Fmoc-leucine-13C6,15N

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Fmoc-leucine-13C6,15N 

Fmoc-leucine-13C6,15N 是一种 15N 标记和 13C 标记的 Fmoc-leucine。Fmoc-leucine 是一种选择性的 PPARγ 调节剂。与罗格列酮相比，Fmoc-leucine 激活 PPARγ 的效力较低，但最大效应相似。Fmoc-leucine 改善正常、饮食诱导的葡萄糖不耐受和糖尿病 db/db 小鼠的胰岛素敏感性。Fmoc-leucine 具有较低的诱导脂肪生成活性。

Fmoc-leucine-13C6,15N

Fmoc-leucine-13C6,15N Chemical Structure

CAS No. : 1163133-36-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Fmoc-leucine-13C6,15N is a 15N-labeled and 13C-labled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[75].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

360.36

Formula

C1513C6H2315NO4
CAS 号

1163133-36-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-248.

    [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-248.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务